Is Schrödinger (SDGR) Undervalued Following Its Profit Turn And Bristol Myers Squibb Deal?
Simply Wall St reports Schrödinger (SDGR) shifted from a loss to a profit in its latest quarterly results and announced an AI-focused deal with Bristol Myers Squibb. The article cites SDGR shares up 22.84% over 7 days and 47.91% over 90 days. It also presents a “fair value” of $20.88 versus a $18.77 close and assumes 11.1% annual revenue growth.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the combination of a fundamental inflection (loss to profit) and a strategic partnership (AI agreement). However, the piece is primarily valuation commentary and does not provide deal financial terms or new guidance figures beyond the profit turnaround framing.
Market read
SDGR is presented as rebounding sharply on earnings improvement and a new AI partnership, but valuation support relies on optimistic forecast assumptions and faces margin and milestone risks.
What to watch
Deal impact is not quantified (no revenue share, milestones, or duration). The article also notes potential software margin pressure and milestone volatility, which could dominate the profit-turn narrative.
Background
Simply Wall St discusses SDGR’s recent earnings swing to profit and a new AI-focused agreement with Bristol Myers Squibb, then overlays a valuation narrative (fair value vs current price).
Ticker impact
Schrödinger reports a quarterly swing from loss to profit and announces an AI-focused agreement with Bristol Myers Squibb, driving renewed valuation debate.
Near-term trading likely remains momentum-driven, with upside capped by concerns about software margin pressure and uncertain milestone timing.
The text provides concrete catalysts (profit turn, new AI agreement) and quantifies recent price performance, but it does not provide deal economics or detailed guidance, limiting conviction on magnitude and durability.
Market effects
Reinforces investor appetite for AI-enabled drug discovery platforms, but also flags software-margin sensitivity to investment shifts.
No specific regional market linkage beyond general US biotech sentiment.
Limited, as the article is company-specific and does not cite cross-border regulatory or market-wide developments.
Counterpoint
The “undervalued” fair value is based on aggressive assumptions (high future revenue growth and an extreme forward P/E), while simpler multiples (P/S) already look expensive.
Key entities
- companySchrödinger
SDGR, discussed as having turned quarterly results to profit and announced an AI-focused agreement with Bristol Myers Squibb.
- companyBristol Myers Squibb
BMS is named as the partner in Schrödinger’s AI-focused agreement.